Stock data
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT) reported net income of -US$48.26M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$51.97M | -US$48.26M | — |
| 2024 | US$0.00M | — | -US$28.59M | -US$27.52M | — |
| 2023 | US$0.26M | — | -US$20.09M | -US$19.03M | — |
| 2022 | US$0.12M | — | -US$18.13M | -US$18.05M | — |
| 2021 | US$3.10M | — | -US$14.77M | -US$14.79M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | -US$19.59M | — |
| 2026-03-31 | US$0.00M | -US$16.38M | — |
| 2025-12-31 | — | -US$12.73M | — |
| 2025-09-30 | US$0.00M | -US$11.93M | — |
| 2025-06-30 | US$0.00M | -US$9.92M | — |
| 2025-03-31 | US$0.00M | -US$13.68M | — |
| 2024-12-31 | US$0.00M | -US$12.13M | — |
| 2024-09-30 | US$0.00M | -US$5.78M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.